Chinese NASH-Focused Biotech Firm Sciwind Biosciences Raises $29M Series A Round

Sciwind Biosciences, a Chinese drug research and development company for metabolic diseases, announced on Wednesday that it has raised a nearly RMB200 million (US$29.58 million) series A round of financing led by Beijing-based investment firm Legend Capital.

(more…)

Chinese NASH-Focused Biotech Firm Sciwind Biosciences Raises $29M Series A Round comes originally from Continue Reading the Entire Article Here >>

This news article comes via China Money Network, who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of

You May Also Like

Matrix Partners-Backed Chinese Commercial Rocket Start-Up iSpace Closes New Round

PICC Invests $353M In Chinese Chauffeured Car Service Firm Ucar

China’s Concord Medical Sets Up $145M Healthcare Fund For Cancer Investments